## **Resource Summary Report**

Generated by FDI Lab - SciCrunch.org on Apr 27, 2025

# CD191 (CCR1) Antibody, anti-human, PE, REAfinity™

RRID:AB\_2655839 Type: Antibody

#### **Proper Citation**

(Miltenyi Biotec Cat# 130-100-367, RRID:AB\_2655839)

#### **Antibody Information**

URL: http://antibodyregistry.org/AB\_2655839

Proper Citation: (Miltenyi Biotec Cat# 130-100-367, RRID:AB\_2655839)

Target Antigen: CD191 (CCR1)

Host Organism: human

Clonality: monoclonal

**Comments:** Applications: MACS Flow Cytometry

Antigen Distribution: macrophages, monocytes, NK cells, T cells, basophils, eosinophils

Antibody Name: CD191 (CCR1) Antibody, anti-human, PE, REAfinity™

**Description:** This monoclonal targets CD191 (CCR1)

Target Organism: human

Clone ID: clone REA158

**Antibody ID:** AB\_2655839

Vendor: Miltenyi Biotec

Catalog Number: 130-100-367

**Record Creation Time:** 20241106T181126+0000

Record Last Update: 20241109T060905+0000

#### **Ratings and Alerts**

No rating or validation information has been found for CD191 (CCR1) Antibody, anti-human, PE, REAfinity™.

No alerts have been found for CD191 (CCR1) Antibody, anti-human, PE, REAfinity™.

### Data and Source Information

**Source:** Antibody Registry

#### **Usage and Citation Metrics**

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Houtsma R, et al. (2021) CombiFlow: Flow cytometry-based identification and characterization of genetically and functionally distinct AML subclones. STAR protocols, 2(4), 100864.

Perna F, et al. (2017) Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML. Cancer cell, 32(4), 506.